Dopamine Receptors: D2 Receptors

D2 receptors are central targets of most established antipsychotics. They usually signal through Gi/o proteins and influence cyclic AMP, ion channels and other cellular processes. They occur on receiving neurons and as autoreceptors involved in regulating dopamine neurons themselves. Their function cannot be summarised as simply switching the brain off.

Dopamine acts through five recognised receptor subtypes: D1, D2, D3, D4 and D5. They are proteins that convert chemical binding into changes inside a cell. D1-like and D2-like families use different signalling pathways, but their overall effects depend on the cells and networks in which they operate.

D2 antagonism can reduce psychotic symptoms but also cause movement difficulties and prolactin elevation through action in other systems. Partial agonists bind to D2 while retaining some activation. Receptor occupancy varies with exposure, and higher occupancy does not always produce greater benefit. Research thresholds are not universal dosing targets. The clinically relevant question is whether a particular treatment provides sufficient symptom relief with acceptable effects on movement, hormones, motivation and everyday functioning for the individual taking it.

D2 effects depend on location. The same general receptor action can reduce psychosis, interfere with movement or elevate prolactin in different systems. This creates a therapeutic trade-off rather than a perfectly selective switch. Assessing symptoms and adverse effects together helps determine whether the exposure provides useful benefit without unnecessarily disrupting other dopamine-dependent functions in the individual.

Further reading: Research record 10739409; Research record 17277774; Research record 8584611; Research record 8935801.